Oxxon Pharmaccines Inc.
This article was originally published in Start Up
Executive Summary
One of the challenges surrounding the development of new vaccines has been inducing a strong enough immune response to protect the recipient from future infections, or to eradicate existing infection. The founding scientists of Oxxon Pharmaccines found that a particular combination of immunizations, using different vectors to deliver the same antigen in a sequence dependent upon priming and timing, created a high T-cell response. The scientists filed a patent around their so-called {Prime-Boost} technology, which has potential in a whole range of diseases, including hepatitis B and melanoma.
You may also be interested in...
On The Cusp: UK Biotech Verona Pharma Awaits Potential Blockbuster
Verona Pharma’s Phase III ensifentrine, if approved, would be the first new dual-mechanism treatment class for COPD patients in decades. It could propel the UK-based biotech toward profitability, or into the arms of a larger partner.
Re-Thinking Rare Disease
Germany is drastically squeezing orphan drug pricing while new US laws protect rare diseases drugs from price negotiations. These contrasting moves fuel the longstanding debate over whether orphans still deserve special incentives.
Bigger Money: Private Equity Grabs European VC
Deals show large investors’ appetite for early-stage biotech, but can VC and PE rub along?